Morgan Stanley
TERN

Morgan Stanley’s Terns Pharmaceuticals TERN Stock Holding History

Morgan Stanley’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$340M Sell
6,449,140
-1,496,468
-19% -$61.5M 0.02% 692
2025
Q4 		$321M Buy
7,945,608
+356,513
+5% +$8.24M 0.02% 709
2025
Q3 		$57M Buy
7,589,095
+335,626
+5% +$2.14M ﹤0.01% 1901
2025
Q2 		$27.1M Buy
7,253,469
+143,364
+2% +$448K ﹤0.01% 2509
2025
Q1 		$19.6M Buy
7,110,105
+3,762,298
+112% +$15.4M ﹤0.01% 2713
2024
Q4 		$18.5M Buy
3,347,807
+2,564,875
+328% +$17.4M ﹤0.01% 2823
2024
Q3 		$6.53M Buy
782,932
+449,314
+135% +$3.7M ﹤0.01% 3750
2024
Q2 		$2.27M Sell
333,618
-253,175
-43% -$1.53M ﹤0.01% 4479
2024
Q1 		$3.85M Sell
586,793
-2,862,619
-83% -$18.7M ﹤0.01% 4121
2023
Q4 		$22.4M Buy
3,449,412
+2,451,652
+246% +$13M ﹤0.01% 3231
2023
Q3 		$5.02M Buy
997,760
+858,170
+615% +$5.45M ﹤0.01% 3736
2023
Q2 		$1.22M Sell
139,590
-2,346
-2% -$27.3K ﹤0.01% 4716
2023
Q1 		$1.68M Buy
141,936
+123,878
+686% +$1.18M ﹤0.01% 4563
2022
Q4 		$184K Buy
18,058
+10,815
+149% +$72K ﹤0.01% 5699
2022
Q3 		$42K Sell
7,243
-11,428
-61% -$42.5K ﹤0.01% 6483
2022
Q2 		$46K Buy
18,671
+10,180
+120% +$20.3K ﹤0.01% 6652
2022
Q1 		$25K Sell
8,491
-80,965
-91% -$346K ﹤0.01% 7049
2021
Q4 		$632K Buy
89,456
+63,412
+243% +$528K ﹤0.01% 5402
2021
Q3 		$271K Sell
26,044
-787
-3% -$8.16K ﹤0.01% 5838
2021
Q2 		$329K Buy
+26,831
New +$457K ﹤0.01% 5757

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Morgan Stanley's TERN Position: Q1 2026 in Review

Morgan Stanley reduced its Terns Pharmaceuticals (TERN) stake by 19% in Q1 2026, selling an estimated $61.5M and leaving 6,449,140 shares worth $340M. The position accounts for 0.02% of the portfolio, ranked #692.

Morgan Stanley first reported a position in TERN in Q2 2021 and has held it in 20 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Morgan Stanley held 6,449,140 shares of Terns Pharmaceuticals worth $340M as of Q1 2026.
  • Morgan Stanley sold 1,496,468 Terns Pharmaceuticals shares in Q1 2026, an estimated $61.5M.
  • Terns Pharmaceuticals made up 0.02% of Morgan Stanley's portfolio in Q1 2026, its #692 holding.
  • Morgan Stanley first reported a position in Terns Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.